CMS' proposed rule seeks to eliminate barriers that prevent Medicare Part D and Medicare Advantage enrollees from accessing lower-cost drugs by giving Part D plans more flexibility to use formulary management tools, such as prior authorizations and step therapy.

The United States Preventive Services Task Force in a draft statement for the first time is recommending that health care providers offer pre-exposure prophylaxis (PrEP) with antiretroviral therapy to patients at high risk for HIV infection—which could make PrEP more accessible to patients.

The medical community celebrated when researchers developed a breakthrough therapy that could fully eliminate hepatitis C, but the treatment's $100,000 price tag prompted Geisinger Health Plan to craft a unique approach to reducing costs.

Harvard Business Review's annual ranking of the 100 "Best-Performing CEOs in the World" includes 11 CEOs in the health care industry.

Sen. Chuck Grassley (R-Iowa) will take over as chair of the Senate Finance Committee in January 2019, and some observers say the move could be bad news for the pharmaceutical industry.

A report from the Senate's Permanent Subcommittee on Investigations found the price of EVZIO, a drug designed to reverse an opioid drug-related overdose, increased from $575 per unit in 2014 to $4,100 per unit in 2017.

Researchers have announced the results of a clinical trial that could lead to the first-ever FDA approval of an oral immunotherapy regimen to reduce children's allergic response to peanuts.

Pfizer says it plans to increase the list prices of 41 of its medical treatments in January, with price increases ranging from 3% to 9%.

American Health Line rounds up the latest health care news in the states.

Forbes this week released its annual 30 Under 30 in health care list, which includes biological researchers, entrepreneurs, physicians, and PhD students under 30 years of age who are working to improve health care delivery in the United States.